摘要
目的探讨奥氮平与奋乃静对老年精神分裂症患者的体重、血糖及血脂等的影响。方法对68例住院的老年精神分裂症患者,随机分成奥氮平与奋乃静治疗组,在12周的治疗的不同时期观察体重、体重指数、腹围、血糖及血脂的变化,同时对两组之间进行以上数据的比较研究。结果奥氮平与奋乃静组都会引起相应的体重、体重指数和腹围及部分血脂值的增加,而奥氮平组的体重及体重指数增加更加明显,奥氮平与奋乃静在对老年精神分裂症患者的腹围、血糖、血脂等方面的影响没有明显的区别。结论非经典抗精神病药物奥氮平与经典抗精神病药物奋乃静都会引起老年精神分裂症患者部分代谢指标的变化,非经典药物对体重等的影响要引起重视。
OBJECTIVE To investigate the changes in body weight and levels of fasting glucose and blood fat in geriatric inpatients with schizophrenia treating with olanzapine or perphenazine. METHODS Sixty-eight geriatric inpatients with schizophrenia were randomly assigned to Olanzapine group or Perphenazine group. The changes in body weight, body mass index (BMI) ,waist circumference, and levels of fasting glucose and blood fat were observed and compared in different period during treatment tmie. RESULTS Both of these two groups showed increase in body weight, waist circumference, BMI and levels of triglyceride and decrease in high density lipoprotein during treat- ment. Although there were no statistical differences emerged in terms of waist circumference, blood glucose and blood fat between these two groups, the olanzapine group showed greater increase in body weight, BMI and waist circumfer- ence compared with perphenazine group. CONCLUSION Atypical antipsychotic medications such as olanzapine in- duce greater weight gain more than typical antipsychotics in treating schizophrenic inpatients, which should be taken seriously by clinicians.
出处
《海峡药学》
2014年第2期82-84,共3页
Strait Pharmaceutical Journal
关键词
老年精神分裂症
体重
血糖
血脂
Geriatric schizophrenia
Olanzapine
Perphenazine
Weight gain
Blood glucose